Anebulo Pharmaceuticals Accounts Payable

Anebulo Pharmaceuticals posts a accounts payable of $550K as of December 2025. That compares with $320K in the prior-year period — up 73.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Anebulo Pharmaceuticals's accounts payable was $320K. The latest reading is $550K — a 73.7% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of Anebulo Pharmaceuticals's financial statement story. At $550K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ANEB's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Anebulo Pharmaceuticals's other metric pages and overview cover the third.

Judging Anebulo Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in accounts payable easier to interpret. Start with $550K here, then scan peer and history charts to see if the gap is persistent.